Phentermine–topiramate extended-release plus lifestyle modification reduced weight and progression to type 2 diabetes mellitus in overweight or obese patients with prediabetes and/or the metabolic syndrome. In the 108-week, phase III trial of 475 patients, progression to type 2 diabetes mellitus was reduced by 71% and 79% in groups receiving two different doses of phentermine–topiramate extended-release, compared with that in the placebo group.
References
Garvey, W. T. et al. Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended-release. Diabetes Care 10.2337/dc13-1518
Rights and permissions
About this article
Cite this article
Phentermine–topiramate extended-release reduces progression to T2DM. Nat Rev Endocrinol 10, 4 (2014). https://doi.org/10.1038/nrendo.2013.217
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2013.217
